A recent study reported better lesion resolution in MOGAD compared with NMOSD-AQP4 or MS, which was not associated with comorbidities, or clinical recovery, but smoking status was not included.5 We found a previously unreported association between MRI lesion resolution and clinical recovery after a relapse in NMOSD-AQP4 and MOGAD, which could highlight the relevance of imaging as a biomarker of tissue damage and recovery. This evidence concerns the gene AQP4 and myeloid sarcoma.